Andrew Amenyogbe1, Francis Lemire1, David Yachnin2, Marc Carrier2,3, Kristen McAlpine4, Rodney H Breau1,2, Dominick Bossé2,5, Tzu-Fei Wang2,3, Christopher Morash1, Ilias Cagiannos1, Luke T Lavallée1,2. 1. Division of Urology, Department of Surgery, University of Ottawa, Ottawa, ON, Canada. 2. The Ottawa Hospital Research Institute, Ottawa, ON, Canada. 3. Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada. 4. Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. 5. Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
Abstract
INTRODUCTION: Patients with advanced bladder cancer receiving chemotherapy have a high risk of venous thromboembolism (VTE); however, we hypothesized these patients were not routinely offered thromboprophylaxis. The objective of this study was to characterize practice patterns and perceptions of Canadian urologic and medical oncologists, and to identify research needs regarding thromboprophylaxis for patients with bladder cancer. METHODS: An online survey was distributed to Canadian urologic and medical oncologists who manage advanced bladder cancer. The survey explored physician opinions regarding VTE rates, risk stratification scores, thromboprophylaxis use in different treatment settings, and interest in clinical trials. RESULTS: Seventy physicians were invited and 36 (51%) completed the survey, including 20 (56%) urologic oncologists and 16 (44%) medical oncologists. Most respondents (35; 97%) believed that exposure to platinum chemotherapy increases VTE risk. For patients receiving neoadjuvant chemotherapy, 34 (94%) respondents estimated the risk of VTE to be 10% or higher, yet 25 (69%) indicated they do not routinely recommend thromboprophylaxis. Physicians frequently (10; 40%) defer the decision to another physician, while eight (32%) believe there is not enough evidence to guide best management. Similar responses were obtained for metastatic patients. Almost all (94%) respondents were interested in participating in a thromboprophylaxis trial for patients with bladder cancer. CONCLUSIONS: Patients with bladder cancer receiving chemotherapy in Canada are not routinely offered thromboprophylaxis. We found strong interest among Canadian oncologists to participate in clinical trials examining this topic.
INTRODUCTION: Patients with advanced bladder cancer receiving chemotherapy have a high risk of venous thromboembolism (VTE); however, we hypothesized these patients were not routinely offered thromboprophylaxis. The objective of this study was to characterize practice patterns and perceptions of Canadian urologic and medical oncologists, and to identify research needs regarding thromboprophylaxis for patients with bladder cancer. METHODS: An online survey was distributed to Canadian urologic and medical oncologists who manage advanced bladder cancer. The survey explored physician opinions regarding VTE rates, risk stratification scores, thromboprophylaxis use in different treatment settings, and interest in clinical trials. RESULTS: Seventy physicians were invited and 36 (51%) completed the survey, including 20 (56%) urologic oncologists and 16 (44%) medical oncologists. Most respondents (35; 97%) believed that exposure to platinum chemotherapy increases VTE risk. For patients receiving neoadjuvant chemotherapy, 34 (94%) respondents estimated the risk of VTE to be 10% or higher, yet 25 (69%) indicated they do not routinely recommend thromboprophylaxis. Physicians frequently (10; 40%) defer the decision to another physician, while eight (32%) believe there is not enough evidence to guide best management. Similar responses were obtained for metastatic patients. Almost all (94%) respondents were interested in participating in a thromboprophylaxis trial for patients with bladder cancer. CONCLUSIONS: Patients with bladder cancer receiving chemotherapy in Canada are not routinely offered thromboprophylaxis. We found strong interest among Canadian oncologists to participate in clinical trials examining this topic.
Authors: Ingrid Pabinger; Nick van Es; Georg Heinze; Florian Posch; Julia Riedl; Eva-Maria Reitter; Marcello Di Nisio; Gabriela Cesarman-Maus; Noémie Kraaijpoel; Christoph Carl Zielinski; Harry Roger Büller; Cihan Ay Journal: Lancet Haematol Date: 2018-06-07 Impact factor: 18.959
Authors: Piotr Zareba; Laurel Patterson; Rishikesh Pandya; David Margel; Sebastien J Hotte; Som D Mukherjee; Leelamma Elavathil; Dean Daya; Bobby Shayegan; Jehonathan H Pinthus Journal: Urol Oncol Date: 2014-07-11 Impact factor: 3.498
Authors: Darren R Brenner; Hannah K Weir; Alain A Demers; Larry F Ellison; Cheryl Louzado; Amanda Shaw; Donna Turner; Ryan R Woods; Leah M Smith Journal: CMAJ Date: 2020-03-02 Impact factor: 8.262
Authors: Kristen McAlpine; Rodney Breau; Marc Carrier; Philippe Violette; Christopher Knee; Ilias Cagiannos; Christopher Morash; Luke Lavallée Journal: Can J Surg Date: 2020-11-30 Impact factor: 2.089
Authors: Gary H Lyman; Marc Carrier; Cihan Ay; Marcello Di Nisio; Lisa K Hicks; Alok A Khorana; Andrew D Leavitt; Agnes Y Y Lee; Fergus Macbeth; Rebecca L Morgan; Simon Noble; Elizabeth A Sexton; David Stenehjem; Wojtek Wiercioch; Lara A Kahale; Pablo Alonso-Coello Journal: Blood Adv Date: 2021-02-23
Authors: James Paul Joseph Ross; Rodney H Breau; Humberto Vigil; Duane R Hickling; Jonathan B Angel; Ranjeeta Mallick; Ilias Cagiannos; Christopher Morash; Luke T Lavallée Journal: Can Urol Assoc J Date: 2021-12 Impact factor: 1.862